Table 2 Definition of response to treatment with Onabotulinumtoxin A (OBT-A) and treatment duration in chronic migraine
Answer options | n (%) |
|---|---|
Reduction in the number of headache days required to define response to OBT-A | |
≥ 30% | 16 (25.4) |
≥ 50% | 37 (58.7) |
< 30% provided that at least one of the following improves: | 10 (15.9) |
• patient satisfaction with treatment and QoL | |
• intensity of headache pain | |
• use of medications for symptom relief | |
• duration of headache attacks | |
Number of treatment cycles administered before considering a patient as a non-responder and discontinuing OBT-A | |
2 | 1 (1.6) |
3 | 35 (55.6) |
4 | 14 (22.2) |
> 4 | 13 (20.6) |
Criteria adopted for discontinuing OBT-A in responders | |
None, as treatment should be maintained in the long-term | 37 (58.7) |
Benefits for ≥6 months | 21 (33.3) |
After 5 treatment cycles | 3 (4.8) |
Achievement of <15 days/month with headache | 2 (3.2) |